Drugs

**Content:** OPD (out-patient department) insurance plays a crucial role in preventive healthcare and early diagnosis. This type of insurance effectively fills a significant gap by covering day-to-day medical expenses, consultations, diagnostic tests, and minor procedures. It’s a vital resource for […]

### Datopotamab Deruxtecan Impresses in Combination Study of Patients with Previously Treated Advanced or Metastatic EGFR-Mutated NSCLC An analysis combining data from the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 studies has shown that datopotamab deruxtecan (Dato-DXd) leads to notable

EpicentRx, a privately-operated biopharmaceutical entity, has disclosed that their investigational therapy, AdAPT-001, has been awarded a Fast Track designation by the US Food and Drug Administration. AdAPT-001, combined with immune checkpoint inhibitors like nivolumab or atezolizumab, targets the treatment of

Pfizer Inc. will feature the latest innovations from its expanding hematology and breast cancer lines at the American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December 10-13). Through over

Cambrex, a prominent global contract development and manufacturing organization (CDMO), has announced a new partnership with Eli Lilly and Company (Lilly) to facilitate speedy access to clinical development resources for Lilly’s biotech partners. In this collaboration, Cambrex will join forces

Global pharmaceutical company Merck, also referred to as MSD outside the US and Canada, has launched the phase 3 MOVe-NOW clinical trial. The trial aims to assess the effectiveness of Lagevrio (molnupiravir), an investigative oral antiviral medication, in treating Covid-19

A study spearheaded by the National Institutes of Health (NIH) has demonstrated that progress in cancer prevention and screening has significantly reduced mortality rates in five common cancer types over the last 45 years, surpassing the impact of advancements in

Novartis has shared favorable initial findings from the APPULSE-PNH study, a Phase IIIB trial that assesses the effectiveness and safety of the twice-daily oral drug Fabhalta (iptacopan) for adults with paroxysmal nocturnal hemoglobinuria (PNH) who previously underwent anti-C5 therapies. Post

The United States Food and Drug Administration has accepted AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), providing it Priority Review status for muscle-invasive bladder cancer (MIBC) treatment. The FDA assigns Priority Review to drug applications that, if approved,

The Karnataka State Registered Pharmacists Association (KSRPA) has urged the government to install an IAS officer in the leadership of the drugs control department by establishing a new non-technical administrative position. “For over ten years, we have been advocating for